The results reveal that ATCV-1 infection significantly accelerated onset and progression of MND in SOD1-G93A-transgenic mice starting at day 141, compared to the PBS-treated transgenic mice, which developed symptoms of MND starting at 150 days (Figure 2A). The gene discussed is SOD1; the disease is mild neurocognitive disorder.